VNDA logo

VNDA
Vanda Pharmaceuticals Inc

5,439
Mkt Cap
$413.76M
Volume
841,978.00
52W High
$9.94
52W Low
$3.81
PE Ratio
-1.87
VNDA Fundamentals
Price
$7.00
Prev Close
$7.10
Open
$7.10
50D MA
$7.59
Beta
0.75
Avg. Volume
1.06M
EPS (Annual)
-$3.74
P/B
1.26
Rev/Employee
$405,450.28
$268.44
Loading...
Loading...
News
all
press releases
AIGH Capital Management LLC Takes Position in Vanda Pharmaceuticals Inc. $VNDA
AIGH Capital Management LLC purchased a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,998,431 shares of the biopharmaceutica...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug
The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December.
Stocktwits·16h ago
News Placeholder
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years Vanda Pharmaceuticals...
PR Newswire·18h ago
News Placeholder
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 PR Newswire WASHINGTON...
PR Newswire·3d ago
News Placeholder
Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Wednesday
Vanda Pharmaceuticals (NASDAQ:VNDA) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-vanda-pharmaceuticals-inc-stock...
MarketBeat·3d ago
News Placeholder
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Crosses Above 200-Day Moving Average - Time to Sell?
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened...
MarketBeat·3d ago
News Placeholder
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Vanda Pharmaceuticals announces the publication of 'Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis' in NEJM Evidence Vanda Pharmaceuticals announces the publication of...
PR Newswire·4d ago
News Placeholder
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +31.29% and +4.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors PR Newswire WASHINGTON, April 22, 2026...
PR Newswire·10d ago
News Placeholder
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average - Time to Sell?
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average - Should You Sell...
MarketBeat·11d ago
<
1
2
...
>

Latest VNDA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.